ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "T-Lymphocyte"

  • Abstract Number: 1661 • ACR Convergence 2024

    Rheumatoid Arthritis Synovial Fibroblast Modulation of T Cell Activation

    Melissa Romoff1, Daniel Ramirez2, Edward Dicarlo3, Susan Goodman4, Alexander Rudenska5, Laura Donlin1 and Melanie Smith1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Cartago, Costa Rica, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery, New York 10025, NY, 5Memorial Sloan Kettering Cancer Center, New York, NY

    Background/Purpose: In the rheumatoid arthritis (RA) joint, resident synovial fibroblasts (FLS) interact with infiltrating leukocytes. We previously identified a population of sublining FLS responsive to…
  • Abstract Number: 1677 • ACR Convergence 2024

    Safety and Efficacy of FNS007, a Non-T Cell Receptor Contacting Peptide, for Patients with Active Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial

    Ru Li1, Xing Sun1, Suping Niu2, Xiaolin Sun1, Guimin Zheng3, Meilu Liu3, Jiyang Lv4, Gengmin Zhou4, Gang Yuan5, Yujin Ye5, Shuang Wang5, Pingfei Fang6, Qi Tang6, Jin Kang6, Xiaoyue Li7, Chao Sun7, Song Zhang7, Yongjun Mei7, Jian Wang7, He Su7, Lijing Huang8, Chenhui Li8, Chao Liu8, Fengxiao Zhang3, Qingwen Wang4, Niansheng Yang5, Fen Li6, Linjie Chen7, Yi Fang2 and Zhanguo Li9, 1Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, 2Clinical Trial Institution, Peking University People’s Hospital, Beijing, China, 3Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, Hebei, China (People's Republic), 4Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (People's Republic), 5Department of Rheumatology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), 6Department of Rheumatology and Immunology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China (People's Republic), 7Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, 8Hebei Fitness Biotechnology Limited Company, Shijiazhuang, Hebei, China (People's Republic), 9Peking univeristy people's hospital, Beijing, China

    Background/Purpose: Long-term drug-free remission is an unmet need for the management of rheumatoid arthritis (RA), which might be achieved by restoring antigen-specific immune tolerance. Autoantigenic…
  • Abstract Number: 0007 • ACR Convergence 2024

    Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation

    Ryota Sato1, Mitsuhiro Akiyama2, Koichi Oshita3, Yuko Kawano3, Yuki Imura3, Piruzyan Mariam4, Manami Kikuchi3, Mikako Murase3, Sachiko Mochiduki3, Naohiro Hashimoto3, Masayuki Watanabe3, Keiko Yoshimoto5, Tsutomu Takeuchi6, Kenji Chiba7 and Yuko Kaneko5, 1Mitsubishi Tanabe Pharma Corporation, Brighton, MA, 2Keio University School of Medicine, Palo Alto, CA, 3Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, 4Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, 5Keio University School of Medicine, Tokyo, Japan, 6Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 7Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan

    Background/Purpose: Proteins motifs bromodomain 1 (BD1) and BD2 within the BET family proteins regulate gene expression of inflammatory cytokines and lymphocyte proliferation by binding to…
  • Abstract Number: 1755 • ACR Convergence 2024

    Single Cell TCR Sequencing Suggests Potential Limitations of TRBV9-depleting Therapies in Axial Spondyloarthritis

    Michael Paley1, Xinbo Yang2, Lynn Hassman1, Grace Paley1, Nicole Linskey1, Ryan Agnew1, Paulo Arantes de Faria1, Annie Feng1, Sophia Li1, Elisha Roberson1, Philip Ruzycki1, Ekaterina Esaulova1, Jennifer Laurent1, Lacey Feigl1, Luke Springer1, Chang Liu1, K. Chris Garcia3 and Wayne Yokoyama4, 1Washington University in St. Louis, Saint Louis, MO, 2Sloan Kettering Institute, New York, NY, 3Stanford, Stanford, CA, 4Washington University School of Medicine, St Louis, MO

    Background/Purpose: TRBV9 depletion is a novel strategy for the treatment of HLA-B27+ axial spondyloarthritis (axSpA) and has achieved clinical remission in at least one patient.…
  • Abstract Number: 0015 • ACR Convergence 2024

    Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution

    Ana Merino Vico1, Yosta Vegting1, Aldo Jongejan1, Jan Piet van Hamburg1, Perry moerland1, Sander Tas2 and Marc Hilhorst1, 1Amsterdam UMC, Amsterdam, Netherlands, 2Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel autoimmune vasculitis, associated with severe lung and kidney impairment. B cells are crucial in AAV…
  • Abstract Number: 1797 • ACR Convergence 2024

    Characterizing Memory T Cell Subsets Associated with SLE Etiopathogenesis

    Carol Nassar1, Rene Quevedo2, M. Teresa Ciudad2, Zoha Faheem3, Kieran Manion4, Carolina Munoz-Grajales5, Michael Kim6, Dafna Gladman7, Murray Urowitz8, Zahi Touma1, Tracy McGaha9 and Joan Wither6, 1University of Toronto, Toronto, ON, Canada, 2Princess Margaret Cancer Centre, Toronto, ON, Canada, 3UHN, Toronto, ON, Canada, 4Toronto Western Hospital, Toronto, ON, Canada, 5UHN/TWH, Toronto, ON, Canada, 6University Health Network, Toronto, ON, Canada, 7University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 8Self employed, Toronto, ON, Canada, 9University Health Network, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease associated with severe morbidity and mortality. Around 70% of SLE patients follow a relapsing-remitting pattern…
  • Abstract Number: 0036 • ACR Convergence 2024

    Deep Topic Modeling Deconvolves Cell States in Spatial Transcriptomic Profiles of Rheumatoid Arthritis Synovial Tissue

    Preethi Periyakoil1, Melanie Smith2, Meghana Kshirsagar3, Daniel Ramirez4, Edward Dicarlo5, Susan Goodman6, Laura Donlin2 and Christina Leslie7, 1Weill Cornell Medical College, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Microsoft AI for Good, Seattle, 4Hospital for Special Surgery, Cartago, Costa Rica, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 6Hospital for Special Surgery, New York 10025, NY, 7Memorial Sloan Kettering Cancer Center, New York, NY

    Background/Purpose: Recent single-cell RNA sequencing (scRNA-seq) studies of the rheumatoid arthritis (RA) synovium have highlighted the heterogeneity of cell states present during active disease. It…
  • Abstract Number: 1837 • ACR Convergence 2024

    Baseline Multiome Sequencing of CD45RO+CD45RA-CD4+ T Cell Reveals Distinct Immune Profiles Associated with Subsequent Response to Secukinumab Treatment

    Addison Pacheco1, Zoya Qaiyum2, Fataneh Tavasolian3, Melissa Lim4, Michael Tang1 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto, ON, Canada, 3Krembil Research Institute - the University Health Network, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: Our study aims to discriminate immune profiles between secukinumab responders (SEC-R) and nonresponders (SEC-NR) in axial spondyloarthritis (axSpA) patients before biologic treatment.Methods: CD45RO+CD45RA-CD4+ T…
  • Abstract Number: 0055 • ACR Convergence 2024

    Activating STAT3 Mutations in CD8+ T Cells Correlate to Serological Positivity in Rheumatoid Arthritis

    Katharine moosic1, Thomas Olson2, Mark Freijat3, samara khalique4, Cait Hamele1, Bryna Shemo1, Jesse Boodoo5, William Baker6, Gitanjali Khurana7, Matthew Schmachtenberg8, Tristin Duffy8, Aakrosh Ratan1, Erika Darrah9, Felipe Andrade10, Marieke Jones8, Kristine Olson2, David Feith1, Thomas Loughran1 and Donald Kimpel1, 1University of Virginia, Charlottesville, VA, 2Virginia Commonwealth University, Richmond, VA, 3Flow Rheumatology, Scottsdale, AZ, 4Carilion Clinic/ VirginiaTech, Salem, VA, 5Sarasota Arthritis Center, Sarasota, FL, 6Atrium Health, Charlotte, NC, 7University of Virginia, CROZET, VA, 8University of Virginia, Charlottesville, 9Johns Hopkins University, Baltimore, MD, 10The Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Large granular lymphocyte (LGL) leukemia is a rare hematologic malignancy characterized by clonal expansion of cytotoxic T-cells and frequent somatic activating STAT3 mutations. A…
  • Abstract Number: 1839 • ACR Convergence 2024

    PPP2R3C Overexpression Suppresses TCR -mediated CD4+ T Cell Abnormal Activation in Systemic Lupus Erythematosus via JNK and AKT-mTOR Pathways

    Xuan Fang, Xiangpei Li and Xiaomei Li, The First Affiliated Hospital of University of Science and Technology of China., He Fei, China (People's Republic)

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is distinguished by immune system dysfunction, leading to heightened activation of T and B cells. This increased activity leads to…
  • Abstract Number: 0079 • ACR Convergence 2024

    Characterization of the Tissue Resident Memorial T Cells in Autoimmune Arthritis: A Comparative Study of Psoriatic Arthritis and Rheumatoid Arthritis

    Siba Raychaudhuri1, Christine Abria2 and Smriti K Raychaudhuri3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2VA Medical Center Sacramento, Mather, CA, 3VA Sacramento Medical Center, Mather, CA

    Background/Purpose: Tissue-resident memory T cells (TRM) cells can drive localized, recurrent inflammation. TRM are site-specific T cells that take up long-term residence in peripheral tissues…
  • Abstract Number: 1846 • ACR Convergence 2024

    Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis

    Amy Anderson1, Henrique de Paula Lemos1, Hendrik Nel2, Sofia Sorbet Santiago1, Fiona Rayner3, Abbie Degnan1, Imogen Wilson1, Julie Diboll1, Jasmine Sim1, Andrew Melville4, Stefan Siebert4, Iain McInnes5, Carl Goodyear4, Catharien Hilkens1, Andrew Filer6, Karim Raza6, Christopher Buckley7, Hugh Reid8, Kenneth Baker1, Arthur Pratt3, Jamie Rossjohn8, Ranjeny Thomas9 and John Isaacs1, 1Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, 3Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, 4School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 5University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 6Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, 7Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 8Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia, 9University of Queensland, Brisbane, Australia

    Background/Purpose: There is a need for immunotherapy that sustains symptom remission without ongoing need for disease modifying drugs (DMARDs). In a phase 1b trial of…
  • Abstract Number: 0305 • ACR Convergence 2024

    Inflammatory T Cell Expansion in Yao Syndrome

    Danielle Xie1, Rimanpreet Kaur2, Richard Kew2, Qingping Yao3 and Charles Vorkas2, 1Stony Brook University, East Setauket, 2Stony Brook University, Stony Brook, 3Stony Brook University, Stony Brook, NY

    Background/Purpose: Yao syndrome (YAOS, #OMIM 617321), formerly known as nucleotide-binding oligomerization protein containing 2 (NOD2)-associated autoinflammatory disease, is associated with specific NOD2 mutations and affects…
  • Abstract Number: 1861 • ACR Convergence 2024

    CD8T Cells Depletion Promotes Human Tph/Tfh Cells Proliferation and Sjogren Syndrome Like Symptoms Without Graft versus Host Diseases in PBMC Transferred-humanized Mice

    Yuzo Koda1, Piruzyan Mariam1, Sota Fujimori1, Ryota Sato2 and Sayuka Kato1, 1Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, 2Mitsubishi Tanabe Pharma Corporation, Brighton, MA

    Background/Purpose: Peripheral helper T (Tph) and follicular helper T (Tfh) cells are known to play a central role in the interaction between T and B…
  • Abstract Number: 0928 • ACR Convergence 2023

    Skewing of B Cell Receptor Repertoire in Unswitched Memory B Cells Is Associated with Disease Activity of Systemic Lupus Erythematosus and Targeted by Belimumab

    Keishi Fujio1, Mineto Ota1, Masahiro Nakano2, Yasuo Nagafuchi3, Satomi Kobayashi1, Hiroaki Hatano2, Ryochi Yoshida1, Yuko Akutsu1, Takahiro Itamiya1, Nobuhiro Ban4, Yumi Tsuchida1, Hirofumi Shoda1, Kazuhiko Yamamoto5, Kazuyoshi Ishigaki6 and Tomohisa Okamura7, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, 3Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 4Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan, 5Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, 6RIKEN, Tokyo, Japan, 7Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    Background/Purpose: Despite the involvement of B cells in the pathogenesis of immune-mediated diseases, the biological mechanisms underlying their function are poorly understood. To address this…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology